- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03530176
18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes (D-NaF)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- University Hospital of Alberta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
> 18 years of age. Has an established diagnosis of diabetes mellitus type 1 or 2. Stable clinical course with a stable medical regimen for 6 months prior to enrollment.
-
Exclusion Criteria:
Unable to give consent. Weight >250 kg. Unable to lie flat for 20-30 minutes to complete the PET-CT session. Pregnancy, breast feeding, known history of primary hyperparathyroidism or metabolic bone disease, recent malignancy (<3 years) or previous thoracic irradiation.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: single arm
18F-NaF (sodium Flouride ) is a radio-pharmaceutical used to image skeletal pathology, including primary and secondary neoplasms.
Despite US Federal Drug Administration (FDA) approval and 18F-NaF being listed in the US Pharmacopeia, 18F-NaF is not currently approved by Health Canada for use as a cardiac imaging tracer.
Therefore, a concurrent Health Canada Clinical Trial Application is being submitted to ensure its availability.
Intervention on single arm: A dose of 18F-NaF (200 - 400 MBq) will be injected intravenously at rest.
After a 60 minute, an ECG-gated PET acquisition will be performed centered over the heart for 20 minutes.
A CT coronary calcium score examination will also be performed on a dedicated CT scanner and the Agatston and volume scores calculated according to standards.
|
The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes
Time Frame: 4-6 weeks
|
Prevalence of patients with type-2 diabetes and unstable, high-risk coronary artery plaques
|
4-6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paolo Raggi, MD, Professor of Medicine, University of Alberta
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Atherosclerosis
- Diabetes Complications
- Physiological Effects of Drugs
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Protective Agents
- Cariostatic Agents
- Listerine
- Fluorides
- Sodium Fluoride
Other Study ID Numbers
- Pro00049579
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on 18Fluoride-Sodium Fluoride radio-isotope
-
Assistance Publique Hopitaux De MarseilleCompleted
-
GlaxoSmithKlineCompletedOral HygieneUnited States
-
GlaxoSmithKlineCompletedOral HygieneUnited States
-
Frank LippertThe Borrow FoundationCompleted
-
GlaxoSmithKlineCompleted
-
University of LeedsCompleted
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloUnknown
-
GlaxoSmithKlineCompleted
-
Khon Kaen UniversityCompletedQuality of Life | Dental Caries in Children | Satisfaction | Oral Health | Cost EffectivenessThailand